Answers are grounded in this paper and cite their sources.
Anatomic imaging alone using standard WHO, RECIST, and RECIST 1.1 criteria have limitations, particularly in assessing the activity of newer cancer therapies that stabilize disease, whereas (18)F-FDG PET appears particularly valuable in such cases. The proposed PERCIST 1.0 criteria should serve as a starting point for use in clinical trials and in structured quantitative clinical reporting. Undoubtedly, subsequent revisions and enhancements will be required as validation studies are undertaken in varying diseases and treatments.
No takes yet. Share an insight, caveat, or question.
Wahl et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: